[1]
|
Jabbour, E. and Kantarjian, H. (2016) Chronic Myeloid Leukemia: 2016 Update on Diagnosis, Therapy, and Monitoring. American Journal of Hematology, 91, 252-265. https://doi.org/10.1002/ajh.24275
|
[2]
|
Druker, B.J., Guilhot, F., O’Brien, S.G., et al. (2006) Five-Year Follow-Up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. The New England Journal of Medicine, 355, 2408-2417. https://doi.org/10.1056/NEJMoa062867
|
[3]
|
Rowley, J.D. (1973) Letter: A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia Identified by Quinacrine Fluorescence and Giemsa Staining. Nature, 243, 290-293. https://doi.org/10.1038/243290a0
|
[4]
|
Shtivelman, E., Lifshitz, B., Gale, R.P., et al. (1985) Fused Transcript of abl and bcr Genes in Chronic Myelogenous Leukaemia. Nature, 315, 550-554. https://doi.org/10.1038/315550a0
|
[5]
|
Daley, G.Q., Van Etten, R.A. and Baltimore, D. (1990) Induction of Chronic Myelogenous Leukemia in Mice by the P210bcr/abl Gene of the Philadelphia Chromosome. Science, 247, 824-830. https://doi.org/10.1126/science.2406902
|
[6]
|
Tura, S., Baccarani, M., Zuffa, E., et al. (1994) Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia. The New England Journal of Medicine, 330, 820-825.
https://doi.org/10.1056/NEJM199403243301204
|
[7]
|
(1997) Interferon Alfa versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-Analysis of Seven Randomized Trials: Chronic Myeloid Leukemia Trialists’ Collaborative Group. Journal of the National Cancer Institute, 89, 1616- 1620. https://doi.org/10.1093/jnci/89.21.1616
|
[8]
|
Kantarjian, H., Shah, N.P., Hochhaus, A., et al. (2010) Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. The New England Journal of Medicine, 362, 2260-2270.
https://doi.org/10.1056/NEJMoa1002315
|
[9]
|
O’Brien, S., Berman, E., Borghaei, H., et al. (2009) NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network, 7, 984-1023.
https://doi.org/10.6004/jnccn.2009.0065
|
[10]
|
Haznedaroglu, I.C. (2015) Drug Therapy in the Progressed CML Patient with Multi-TKI Failure. Mediterranean Journal of Hematology and Infectious Diseases, 7, e2015014. https://doi.org/10.4084/mjhid.2015.014
|
[11]
|
Ernst, T. and Hochhaus, A. (2012) Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated with Disease Progression. Seminars in Oncology, 39, 58-66.
https://doi.org/10.1053/j.seminoncol.2011.11.002
|
[12]
|
Kim, T.D., Türkmen, S., Schwarz, M., et al. (2010) Impact of Additional Chromosomal Aberrations and BCR-ABL Kinase Domain Mutations on the Response to Nilotinib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. Haematologica, 95, 582-588. https://doi.org/10.3324/haematol.2009.014712
|
[13]
|
Baccarani, M., Cortes, J., Pane, F., et al. (2009) Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European Leukemia Net. Journal of Clinical Oncology, 27, 6041-6051.
https://doi.org/10.1200/JCO.2009.25.0779
|
[14]
|
Zhou, L., Shi, H., Jiang, S., et al. (2016) Deep Molecular Response by IFN-α and Dasatinib Combination in a Patient with T315I-Mutated Chronic Myeloid Leukemia. Pharmacogenomics, 17, 1159-1163.
https://doi.org/10.2217/pgs-2016-0049
|
[15]
|
Hjorth-Hansen, H., Stentoft, J., Richter, J., et al. (2016) Safety and Efficacy of the Combination of Pegylated Interferon-α2b and Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients. Leukemia, 30, 1853- 1860. https://doi.org/10.1038/leu.2016.121
|
[16]
|
Essers, M.A., Offner, S., Blanco-Bose, W.E., et al. (2009) IFNalpha Activates Dormant Haematopoietic Stem Cells in Vivo. Nature, 458, 904-908. https://doi.org/10.1038/nature07815
|
[17]
|
Cornelissen, J.J., Ploemacher, R.E., Wognum, B.W., et al. (1998) An in Vitro Model for Cytogenetic Conversion in CML. Interferon-Alpha Preferentially Inhibits the Outgrowth of Malignant Stem Cells Preserved in Long-Term Culture. Journal of Clinical Investigation, 102, 976-983. https://doi.org/10.1172/JCI2366
|